chevron_leftBack
As of 24 April 2025, Hunan Jingfeng Pharmaceutical Co.,Ltd. has a market cap of $613.32M USD, ranking #10746 globally and #3267 in China. It ranks #1042 in the Healthcare sector, and #51 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$613.32MUSD
4.47B CNY
Enterprise Value
$677.14MUSD
4.93B CNY
Revenue (TTM)
$54.59MUSD
397.76M CNY
EBITDA (TTM)
-$15.11MUSD
-110.12M CNY
Net Income (TTM)
-$39.25MUSD
-286.0M CNY
EBITDA Margin
-28%
Profit Margin
-72%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Xiang Wu Ye
open_in_new
Employees
572
Founded
2003
Website
jfzhiyao.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 4.9% | 16% | 9.3% | 16% | 28% | 217% |
Upcoming Earnings
Earnings Date
Tue, Apr 29
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
000908
湖南景峰医药股份有限公司 Class A
ISIN: CNE000000Y11
Shares Out.:
Shares Outstanding:
879.774M1
Shares Float:
833.893M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
5.33 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hunan Jingfeng Pharmaceutical Co.,Ltd.
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company’s principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. In addition, the company provides CDMO/CMO services. The company was founded in 2003 and is headquartered in Shanghai, China.
